Navigation Links
Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
Date:9/12/2007

STEWARTVILLE, Minn., Sept. 12 /PRNewswire-FirstCall/ -- Rochester Medical Corporation (Nasdaq: ROCM) announced today the publication of results from a significant clinical study which further demonstrates the effectiveness of the Company's proprietary Infection Control Technology.

The newly released September issue of the "Annals of Internal Medicine" presents results of a randomized, double-blind, controlled clinical trial involving 212 adult patients at Denmark's Copenhagen Trauma Center. The study concluded nitrofurazone-impregnated urinary catheters reduced the incidence of catheter-associated bacteriuria and funguria in adult trauma patients, reducing the need to change or prescribe new antimicrobial therapy.

The nitrofurazone-impregnated urinary catheters used in the study were manufactured by Rochester Medical. The control catheter was an all-silicone Foley catheter. The study was conducted by Jakob Stensballe, PhD; Michael Tvede, MD; Dagnia Looms, PhD; Freddy Knudsen Lippert, MD; Benny Dahl, DMSc; Else Tonnesen, DMSc; and Lars Simon Rasmussen, PhD.

Commenting on the peer-reviewed publication of this clinical study, Rochester Medical's CEO and President - Anthony J. Conway said, "This is more good news in the ongoing effort to reduce serious infections in hospitals around the world. There is now published data from the United States, Denmark, South Korea, Spain, and Saudi Arabia showing the effectiveness of our All Silicone Anti-Infection Foley Catheters."

Conway continued, "Hospital acquired infections are a serious problem across the globe. In the United States alone it is estimated these infections cause over 90,000 deaths a year. The Center for Disease Control estimates 40% of all ho
'/>"/>

SOURCE Rochester Medical Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)... ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/...hat it has completed enrollment in the Phase I/IIa... a total of approximately,230 subjects. Favorable ...,which included dose-escalation in 70 healthy adul...interim findings suggested that the vaccine,is wel...
(Date:5/15/2008)... Medicare Advantage Fee-For-Service Plan Positions...w Business, According to a New Report from ...LE, Tenn., May 15 /- HealthLeaders-In...ket intelligence, reports that as the,economy cont...eld of,Michigan remains the best equipped of all o...
(Date:5/15/2008)... Randomized TRIAS HR Pilot Study Compares Geno... Taxus(R), Other Presentations Focus on Real-W...ts with AMI, Those Who Could Not Tolerate Dual-Ant... BARCELONA, Spain, May 15 /- OrbusNei...sentations in a symposium at EuroPCR 2008,support ...
(Date:5/15/2008)... GREEN BAY, Wis., May 15 /- Omega...be further considered as a credible natural,altern...y in ADHD patients,recent in vivo French study re...ial effects of omega-3 in hyperactivity, French re...d have specific positive effects on,impulse contro...
Breaking Medicine Technology:Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3New Computerized Scans Effective for Spotting Clogged Arteries 5516 1New Computerized Scans Effective for Spotting Clogged Arteries 5516 2New Computerized Scans Effective for Spotting Clogged Arteries 5516 3Baxter Kidney Patient Education Program Celebrates Tenth Anniversary 1687 1Baxter Kidney Patient Education Program Celebrates Tenth Anniversary 1687 2Baxter Kidney Patient Education Program Celebrates Tenth Anniversary 1687 3Baxter Kidney Patient Education Program Celebrates Tenth Anniversary 1687 4Keryx Biopharmaceuticals Inc Announces Positive Preliminary Phase 2 Data on KRX 0401 in Patients with Chemo Insensitive Rare Sarcoma 752 1Keryx Biopharmaceuticals Inc Announces Positive Preliminary Phase 2 Data on KRX 0401 in Patients with Chemo Insensitive Rare Sarcoma 752 2Keryx Biopharmaceuticals Inc Announces Positive Preliminary Phase 2 Data on KRX 0401 in Patients with Chemo Insensitive Rare Sarcoma 752 3Keryx Biopharmaceuticals Inc Announces Positive Preliminary Phase 2 Data on KRX 0401 in Patients with Chemo Insensitive Rare Sarcoma 752 4Keryx Biopharmaceuticals Inc Announces Positive Preliminary Phase 2 Data on KRX 0401 in Patients with Chemo Insensitive Rare Sarcoma 752 5Keryx Biopharmaceuticals Inc Announces Positive Preliminary Phase 2 Data on KRX 0401 in Patients with Chemo Insensitive Rare Sarcoma 752 6Progen Presents Additional Analysis of Data from PI 88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 749 1Progen Presents Additional Analysis of Data from PI 88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 749 2Progen Presents Additional Analysis of Data from PI 88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 749 3
(Date:5/16/2008)...thyroid hormone readings, study says , ,...vitamin D and high levels of a hormone secreted by...epression in older adults, according to a new repo...sue of Archives of General Psychiatry , supports ..., depression and other psychiatric illnesses are l...
(Date:5/16/2008)...wswire/ -- This release is,being sent in a social ...he,National Cancer Institute, part of the NIH., N...an Society of Clinical,Oncology meeting in Chicago...n about 25 percent of patients with colon cancer a...lorectal cancers will be staged., * This new stud...
(Date:5/16/2008)...ASHINGTON, May 16 /PRNewswire-USNewswire/ -- More ...ans in the Greater Portland, Oregon and,Vancouver,...ntract as,Teamsters., "The Teamsters are pleased ...tract that gives them job protection and a secure ...nt Jim Hoffa., The workers, both full-time and pa...
(Date:5/16/2008)... Phase III clinical trial has found that the exper...ficantly delays cancer progression in patients wit...ned on other treatments. The study was led by Rob... Sloan-Kettering Cancer Center (MSKCC), who will p...g of the American Society for Clinical Oncology. ,...
Breaking Medicine News(10 mins):Health News:Low Vitamin D Tied to Depression in Older Adults 2Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Drug fends off kidney cancer progression 2
... continues to fuel research, as the incidence is l...en developed to slow the course of Alzheimer's dis..., which is one of the brain’s messenger and this c... Learning and memory are the fields, which are ena...
...und that two overlapping genes responsible for bip... the genes increases risk for schizophrenia. This ...e for both disorders. Bipolar disorder, also known... that causes shifts in a person's mood, with spurt...
...icates that Negative exercise electrocardiograph t...atification of hypertensive patients with chest pa... at low risk, positive findings could not distingu...hat pharmacological stress echocardiography yielde...
...und that mothers suffering from postpartum depress...ave infants with healthy weight gain when compared...ings suggest women should seek treatment even if t...eding. Postpartum depression in the first six mont...
Other Medicine News:
The latest from the leader in automatic slide stainers. It offers a truly unique and modern approach to slide staining, ending messy procedures. The instrument of choice for peripheral blood smears,
Cholesterol single reagent. Storage temp: 2 - 8 C. Linearity: 0 - 600 mg. Expected values: Recommended 240 mg/dL. Available with calibrator and performed 500 number of test.
For the quantitative determination of total cholesterol in serum.
Intended for the quantitative determination of total cholesterol in serum. Reaction: Endpoint. Reaction complete within five minutes. Wavelength: 500 nm. Linearity: 700 mg/dL (18.1 mmol/L). Single st
Medicine Products: